Monday, July 23, 2018
 
 
Company News: Page (1) of 1 - 08/04/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Nephrology Associates Acquires Signature Nephrology
 
(August 04, 2017)
Nephrology Associates Acquires Signature Nephrology

Nephrology Associates, PC announced today the acquisition of Signature Nephrology. This acquisition allows patients of middle Tennessee to continue to receive excellent treatment for chronic kidney disease, kidney transplant, kidney stones, dialysis (home and in-center), hypertension, diabetic nephropathy, lupus nephritis, proteinuria, polycystic kidney disease and pregnancy related renal issues.

Patients from Signature Nephrology will have access to Nephrology Associates' multiple outpatient clinic locations in middle Tennessee, as well as provider presence in over 20 area hospitals and rehabilitation facilities.

No additional terms of the transaction were disclosed.



Read the full story at http://www.prweb.com/releases/2017/08/prweb14569288.htm.


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Healthcare IT Market 2018 - 2023 with SWOT Analysis regarding upcoming Changes and Technology Adaptations in Global Healthcare Sector
  • Sciatica Market Research Valued 18.9 Billion US$ by 2023: A Comprehensive Sciatica Market Growth by by type, by Drug Treatment and by End User
  • Medical Sensors Market to be Worth US$18.74 Billion by 2023, Says TMR
  • Vision Care Product Market To Witness Enhanced Growth Owing To Rising Occurrence Of Eye Disorders Till 2021 | Million Insights
  • Global Prosthetic Heart Valve Market Reaching at a CAGR of +12.70% by Geography, Deployment Model, Component, and Key players are Boston Scientific Cardiology, CryoLife, Inc., Abbott

    Cancer
  • CStone Pharmaceuticals Appoints Former Goldman Sachs Executive Richard Yeh as CFO
  • CytRx Corporation Announces Expiration of Outstanding Warrants
  • HedgePath Pharmaceuticals Granted Exclusive Option to License UCONN's Patented Chemical Analogues of Itraconazole
  • Alligator Bioscience Submits Application to Start Clinical Phase I Study in Cancer Patients with ATOR-1015, a Unique CTLA-4 and OX40 Binding Antibody
  • Yisheng Biopharma Announces Opening of New Business Divisions in Cambodia, Expanding Presence within Southeast Asia
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines